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On superficial analysis, the results presented by Rowan et al (2008)
might suggest that there is a cause for celebration. Surely a major
increase in survival in a disease, which is the biggest killer of men
in the United Kingdom, shows that diagnosis and treatment is
getting better? Before we get too elated, however, we should
perhaps pause for thought, for as the authors rightly point out,
there are important reasons why the results appear to be so good.
The data confirm that for the United Kingdom, like other
developed countries, diagnostic rates for prostate cancer have risen
sharply in the last two decades. This phenomenon has emerged
outside the United Kingdom as a consequence of population-based
screening using the serum PSA test (Merrill and Stephenson, 2000)
and although this type of systematic cancer testing is not carried
out in the United Kingdom, it is well known that opportunistic
PSA testing has become widespread and that there is considerable
‘case finding’ in asymptomatic men as a consequence (Melia et al,
2004; Gavin et al, 2004). It is therefore no surprise to see that the
rate of diagnosis in the United Kingdom is going up, as has been
shown in this study. It is also well known that this epidemiological
trend has lead to a ‘stage shift’, with diagnosis and treatment
occurring earlier in the natural history of the disease in many men
(Andriole et al, 2006).
In interpreting evolving epidemiological trends in this area, it is
also important to consider the underlying change in mortality.
Clearly, there are potential errors inherent in correlating relative
survival (the interval between diagnosis and all causes of death)
with the prostate cancer-specific death rate (cause of death as
recorded on a death certificate) and it would be inappropriate to
correlate the changes in survival and mortality too rigidly.
Nonetheless, it is important to note that although prostate
cancer-related mortality has decreased slightly in the United
Kingdom and in other parts of the developed world over this time
period, it has not changed fundamentally (Cancer Research UK,
2007). It is also important to consider the well-described lead-time
effect (the time difference between screen-based detection and
clinical detection in the absence of screening) in prostate cancer,
which is relevant in this population and has been estimated to be
in the region of 10 years or more (Draisma et al, 2003). It is
possible that this and other phenomena may have a significant
bearing on the changes observed in this report.
The effects of treatment on this population are difficult to
quantify. The authors largely discount any treatment effect in their
analysis, although it is not possible, on the basis of the information
presented, to determine whether a therapeutic component has
contributed in some way to the observed survival improvements.
The explicit statement that there has been no ‘substantially
improved treatment’ for prostate cancer is not strictly true. There
is level 1 evidence to show that surgical treatment has a beneficial
effect in terms of absolute survival in localised disease (Bill-
Axelson et al, 2005) and in treatment schemes using combined
adjuvant hormone and radiation therapy for high-risk locally
advanced disease Bolla et al, 2002). Interventions in late-stage
disease are also much more widespread (Khafagy et al, 2007).
Thus, therapeutic intervention may well have made a contribution
to the observed effect in the patient population studied. That being
said, it is likely that this effect would have been relatively small and
that other factors, such as lead time rather than specific treatment
intervention, have been the major contributory factors to the
dramatic changes documented.
The results in relation to different socioeconomic groups are of
interest. In considering the ‘difference in survival’ in the affluent
and deprived groups it is again critical to look at the differential
rates of diagnosis. If the number of low-risk ‘screening type’
cancers is lower in the less affluent group, then their survival
relative to that in the more affluent groups may seem worse. There
are reasons why the diagnostic rate may be much lower in the
deprived groups. Deprived populations are known to have a lower
rate of uptake for early diagnostic techniques such as PSA testing
(Wannamethee and Shaper, 1997) and this is borne out by
evidence that the presentation of men with prostate cancer has not
changed over a number of years in some deprived populations,
notwithstanding the advent of PSA testing (Mokete et al, 2005).
Rowan et al (2008) suggest that affluent men may have ‘greater
access’ to PSA tests. There is some evidence that this may be true;
Mokete et al (2005) also showed that the rate of testing may be
lower by a factor of almost 50% in deprived communities, although
it is not clear whether this is owing to lack of availability of the test
from General Practitioners or whether men in this particular social
group simply do not come forward for testing.
But has this disadvantaged the socially deprived male? It is
interesting to reflect that they, as a group, may have been spared
the physical and psychological effects of overtreatment, which
are currently problematic in early prostate cancer in some
countries (Carroll, 2005) and furthermore, the type of tumour
more likely to have been detected would have been low-volume/
low-risk prostate cancer (Parker et al, 2006) with a good prognosis
in the long term (Albertson et al, 2005). In this sense, the socially
deprived male may, for once, have emerged better off than his
affluent counterpart. However, other men in this group, whose
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Overall, the point remains that improvements in survival
patterns are encouraging but lead time and early diagnosis of
greater numbers of patients with low-stage/low-risk prostate
cancer may have a significant bearing on this. It is fundamentally
important to emphasise that the overall death rate is a critically
important figure and to remember that this disease is still
responsible for one cancer death in eight in men in the United
Kingdom. There is still no effective curative treatment for clinically
aggressive prostate cancer. Recently, an analysis comparing SEER
data with UK Hospital Episode Statistics (HES) has shown a
relatively static picture in the United Kingdom compared with
more rapid improvements in absolute death rates, which may have
resulted from more aggressive treatment policies in the United
States for both early and late disease (Collin et al, 2008).
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